Leaders in Pharmaceutical Business Intelligence (LPBI) Group

New Frontiers in Gene Editing — Cambridge Healthtech Institute’s Inaugural, February 19-20, 2015 | The Inter Continental San Francisco | San Francisco, CA

Reporter: Aviva Lev-Ari, PhD, RN

 

Gene editing is rapidly progressing from being a research/screening tool to one that promises important applications downstream in drug development and cell therapy. Cambridge Healthtech Institute’s inaugural symposium on New Frontiers in Gene Editing will bring together experts from all aspects of basic science and clinical research to talk about how and where gene editing can be best applied. What are the different tools that can be used for gene editing, and what are their strengths and limitations? How does the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas system, compare to Transcription Activator-like Effector Nucleases (TALENs), zinc finger nucleases (ZFNs) and other systems and where are they being used? Scientists and clinicians from pharma/biotech as well as from academic and government labs will share their experiences leveraging the utility of gene editing for functional screening, creating cell lines and knock-outs for disease modeling, and for cell therapy.

 

KEYNOTE PRESENTATIONS:

Precise Single-Base Genome Engineering for Human Diagnostics and Therapy

Bruce R. Conklin M.D., Investigator, Roddenberry Center for Stem Cell Biology and Medicine, Gladstone Institutes and Professor, Division of Genomic Medicine, University of California, San Francisco

Genome Edited Induced Pluripotent Stem Cells for Drug Screening

Joseph C. Wu, M.D., Ph.D., Director, Stanford Cardiovascular Institute and Professor, Department of Medicine/Cardiology & Radiology, Stanford University School of Medicine

 

USING GENE EDITING FOR FUNCTIONAL SCREENS

Exploration of Cellular Stress and Trafficking Pathways Using shRNA and CRISPR/Cas9-based Systems

Michael Bassik, Ph.D., Assistant Professor, Department of Genetics, Stanford University

Gene Editing in Patient-derived Stem Cells for In Vitro Modeling of Parkinson’s Disease

Birgitt Schuele M.D., Associate Professor and Director of Gene Discovery and Stem Cell Modeling, The Parkinson’s Institute

Massively Parallel Combinatorial Genetics to Overcome Drug Resistance in Bacterial Infections and Cancer

Timothy K. Lu, M.D., Ph.D., Associate Professor, Synthetic Biology Group, Department of Electrical Engineering and Computer Science and Department of Biological Engineering, Synthetic Biology Center, Massachusetts Institute of Technology

 

TRANSLATING GENE EDITING IN VIVO

CRISPR-Cas: Tools and Applications for Genome Editing

Fei Ann Ran, Ph.D., Post-doctoral Fellow, Laboratory of Dr. Feng Zhang, Broad Institute and Junior Fellow, Harvard Society of Fellows

Anti-HIV Therapies: Genome Engineering the Virus and the Host

Paula M. Cannon Ph.D., Associate Professor, Molecular Microbiology & Immunology, Biochemistry, and Pediatrics, Keck School of Medicine, University of Southern California

Preventing Transmission of Mitochondrial Diseases by Germline Heteroplasmic Shift Using TALENs

Juan Carlos Izpisua Belmonte, Ph.D., Professor, Gene Expression Laboratory, Salk Institute

Nuclease-Based Gene Correction for Treating Single Gene Disorders

Gang Bao, Ph.D., Professor, Robert A. Milton Chair in Biomedical Engineering, Department of Biomedical Engineering, Georgia Institute of Technology and Emory University

 

EXPLORING GENE EDITING FOR THERAPEUTIC USES

Gene Editing on the Cusp of Exciting Opportunities for Human Therapeutics

Rodger Novak, M.D., CEO, CRISPR Therapeutics

Genome Editing for Genetic Diseases of the Blood

Matthew Porteus, M.D., Ph.D., Associate Professor, Pediatrics, Stanford University School of Medicine

Genome Engineering Tools for Gene Therapy and Regenerative Medicine

Charles A. Gersbach, Ph.D., Assistant Professor, Department of Biomedical Engineering, Center for Genomic and Computational Biology, Duke University

 

INTELLECTUAL PROPERTY LANDSCAPE: OPPORTUNITIES & CONCERNS

CRISPR/Cas-9: Navigating Intellectual Property (IP) Challenges in Gene Editing

Chelsea Loughran, Associate, Litigation Group, Wolf, Greenfield and Sacks, P.C.

Suggested Event Package:

February 15 Afternoon Short Course: Best Practices in Personalized and Translational Medicine
February 15 Dinner Short Course: Regulatory Compliance in Drug-Diagnostics Co-Development
February 16 Morning Short Course: Isolation and Characterization of Cancer Stem Cells
February 16-18 Conference Program: Genome and Transcriptome Analysis

 

 

For more details on the conference, please contact: 
Tanuja Koppal, Ph.D.,
Conference Director
Cambridge Healthtech Institute
E: tkoppal@healthtech.com

For partnering and sponsorship information, please contact: 
Jon Stroup (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com

Joseph Vacca (Companies L-Z)
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com

SOURCE

http://www.triconference.com/gene-editing

From: Gene Editing <davem@healthtech.com>
Date: Wed, 27 Aug 2014 12:58:56 -0400
To: <avivalev-ari@alum.berkeley.edu>
Subject: New Frontiers in Gene Editing [preliminary agenda just released]